Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer

Cell

Volumn 171, Issue 6, 2017, Pages 1284-1300.e21

  Topper, Michael J ^a   Vaz, Michelle ^a   Chiappinelli, Katherine B ^b   DeStefano Shields, Christina E ^a   Niknafs, Noushin ^a   Yen, Ray Whay Chiu ^a   Wenzel, Alyssa ^e   Hicks, Jessica ^a   Ballew, Matthew ^a   Stone, Meredith ^a   Tran, Phuoc T ^a   Zahnow, Cynthia A ^a   Hellmann, Matthew D ^c   Anagnostou, Valsamo ^a   Strissel, Pamela L ^d   Strick, Reiner ^d   Velculescu, Victor E ^a   Baylin, Stephen B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

azacitidine; HDAC; immune response; ITF 2357; lung cancer; memory T cells; MYC; NSCLC

Indexed keywords

ALPHA INTERFERON; ANTIGEN; AZACITIDINE; BETA INTERFERON; CHEMOATTRACTANT; DNA METHYLTRANSFERASE INHIBITOR; DOUBLE STRANDED RNA; ENTINOSTAT; GIVINOSTAT; HISTONE DEACETYLASE INHIBITOR; ISOPROTEIN; MOCETINOSTAT; MYC PROTEIN; RANTES; RGFP 996; TUBASTATIN A; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GIVINOSTAT HYDROCHLORIDE; HYDROXAMIC ACID; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; ENZYME REPRESSION; ENZYME SPECIFICITY; EPIGENETICS; EXHAUSTION; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNE EVASION; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG CANCER CELL LINE; LYMPHOCYTE PROLIFERATION; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; UPREGULATION; ANIMAL; ANTIGEN PRESENTATION; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; T LYMPHOCYTE; TUMOR CELL LINE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGEN PRESENTATION; ANTINEOPLASTIC AGENTS; AZACITIDINE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG THERAPY, COMBINATION; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; IMMUNOTHERAPY; LUNG NEOPLASMS; MICE; T-LYMPHOCYTES; TRANSCRIPTOME; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85036532572     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.10.022     Document Type: Article

References (55)

1. Anagnostou, V., Smith, K.N., Forde, P.M., Niknafs, N., Bhattacharya, R., White, J., Zhang, T., Adleff, V., Phallen, J., Wali, N., et al. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov. 7 (2017), 264–276.
2. Asthana, J., Kapoor, S., Mohan, R., Panda, D., Inhibition of HDAC6 deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells. J. Biol. Chem. 288 (2013), 22516–22526.
3. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., Vokes, E.E., Felip, E., Holgado, E., et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 373 (2015), 1627–1639.
4. Bradner, J.E., West, N., Grachan, M.L., Greenberg, E.F., Haggarty, S.J., Warnow, T., Mazitschek, R., Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 6 (2010), 238–243.
5. Cai, Y., Geutjes, E.J., de Lint, K., Roepman, P., Bruurs, L., Yu, L.R., Wang, W., van Blijswijk, J., Mohammad, H., de Rink, I., et al. The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes. Oncogene 33 (2014), 2157–2168.
6. Cai, Y., Tsai, H.C., Yen, R.C., Zhang, Y.W., Kong, X., Wang, W., Xia, L., Baylin, S.B., Critical threshold levels of DNA methyltransferase 1 are required to maintain DNA methylation across the genome in human cancer cells. Genome Res. 27 (2017), 533–544.
7. Cameron, E.E., Bachman, K.E., Myöhänen, S., Herman, J.G., Baylin, S.B., Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21 (1999), 103–107.
8. Casey, S.C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K.N., Gouw, A.M., Baylot, V., Gütgemann, I., Eilers, M., Felsher, D.W., MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352 (2016), 227–231.
9. Cheng, Z., Gong, Y., Ma, Y., Lu, K., Lu, X., Pierce, L.A., Thompson, R.C., Muller, S., Knapp, S., Wang, J., Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin. Cancer Res. 19 (2013), 1748–1759.
10. Chiappinelli, K.B., Strissel, P.L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N.S., Cope, L.M., Snyder, A., et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell 162 (2015), 974–986.
11. Falkenberg, K.J., Johnstone, R.W., Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13 (2014), 673–691.
12. Fournel, M., Bonfils, C., Hou, Y., Yan, P.T., Trachy-Bourget, M.C., Kalita, A., Liu, J., Lu, A.H., Zhou, N.Z., Robert, M.F., et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer Ther. 7 (2008), 759–768.
13. Furlan, A., Monzani, V., Reznikov, L.L., Leoni, F., Fossati, G., Modena, D., Mascagni, P., Dinarello, C.A., Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol. Med. 17 (2011), 353–362.
14. Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al., KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 2018–2028.
15. Ghoneim, H.E., Fan, Y., Moustaki, A., Abdelsamed, H.A., Dash, P., Dogra, P., Carter, R., Awad, W., Neale, G., Thomas, P.G., Youngblood, B., De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell 170 (2017), 142–157.e19.
16. Gore, L., Rothenberg, M.L., O'Bryant, C.L., Schultz, M.K., Sandler, A.B., Coffin, D., McCoy, C., Schott, A., Scholz, C., Eckhardt, S.G., A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin. Cancer Res. 14 (2008), 4517–4525.
17. Hong, M., Puaux, A.L., Huang, C., Loumagne, L., Tow, C., Mackay, C., Kato, M., Prévost-Blondel, A., Avril, M.F., Nardin, A., Abastado, J.P., Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res. 71 (2011), 6997–7009.
18. Huang da, W., Sherman, B.T., Lempicki, R.A., Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37 (2009), 1–13.
19. Huang da, W., Sherman, B.T., Lempicki, R.A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4 (2009), 44–57.
20. Huang, Y., Yuan, J., Righi, E., Kamoun, W.S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J.D., Martin, M.R., Vianello, F., et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. USA 109 (2012), 17561–17566.
21. Huang, Y., Goel, S., Duda, D.G., Fukumura, D., Jain, R.K., Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 73 (2013), 2943–2948.
22. Jackson, E.L., Willis, N., Mercer, K., Bronson, R.T., Crowley, D., Montoya, R., Jacks, T., Tuveson, D.A., Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15 (2001), 3243–3248.
23. Jones, P.A., Issa, J.P., Baylin, S., Targeting the cancer epigenome for therapy. Nat. Rev. Genet. 17 (2016), 630–641.
24. Juergens, R.A., Wrangle, J., Vendetti, F.P., Murphy, S.C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C.M., Franco, N., et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 1 (2011), 598–607.
25. Kellar, A., Egan, C., Morris, D., Preclinical Murine Models for Lung Cancer: Clinical Trial Applications. BioMed Res. Int., 2015, 2015, 621324.
26. Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S.C., Carey, N., et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409 (2008), 581–589.
27. Krämer, O.H., Baus, D., Knauer, S.K., Stein, S., Jäger, E., Stauber, R.H., Grez, M., Pfitzner, E., Heinzel, T., Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev. 20 (2006), 473–485.
28. Lavergne, E., Combadière, C., Iga, M., Boissonnas, A., Bonduelle, O., Maho, M., Debré P., Combadiere, B., Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J. Immunol. 173 (2004), 3755–3762.
29. Li, H., Chiappinelli, K.B., Guzzetta, A.A., Easwaran, H., Yen, R.W., Vatapalli, R., Topper, M.J., Luo, J., Connolly, R.M., Azad, N.S., et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5 (2014), 587–598.
30. Malvaez, M., McQuown, S.C., Rogge, G.A., Astarabadi, M., Jacques, V., Carreiro, S., Rusche, J.R., Wood, M.A., HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc. Natl. Acad. Sci. 110 (2013), 2647–2652.
31. Moran, C.J., Arenberg, D.A., Huang, C.C., Giordano, T.J., Thomas, D.G., Misek, D.E., Chen, G., Iannettoni, M.D., Orringer, M.B., Hanash, S., Beer, D.G., RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin. Cancer Res. 8 (2002), 3803–3812.
32. Moreno-Bost, A., Szmania, S., Stone, K., Garg, T., Hoerring, A., Szymonifka, J., Shaughnessy, J. Jr., Barlogie, B., Prentice, H.G., van Rhee, F., Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103. Cytotherapy 13 (2011), 618–628.
33. Oi, S., Natsume, A., Ito, M., Kondo, Y., Shimato, S., Maeda, Y., Saito, K., Wakabayashi, T., Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2′-deoxycytidine in glioma cells. J. Neurooncol. 92 (2009), 15–22.
34. Okayama, H., Saito, M., Oue, N., Weiss, J.M., Stauffer, J., Takenoshita, S., Wiltrout, R.H., Hussain, S.P., Harris, C.C., NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression. Int. J. Cancer 132 (2013), 9–18.
35. Rasheed, W.K., Johnstone, R.W., Prince, H.M., Histone deacetylase inhibitors in cancer therapy. Expert Opin. Investig. Drugs 16 (2007), 659–678.
36. Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al., KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 375 (2016), 1823–1833.
37. Ribas, A., Shin, D.S., Zaretsky, J., Frederiksen, J., Cornish, A., Avramis, E., Seja, E., Kivork, C., Siebert, J., Kaplan-Lefko, P., et al. PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol. Res. 4 (2016), 194–203.
38. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
39. Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S.Y., Han, H., Liang, G., Jones, P.A., Pugh, T.J., et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell 162 (2015), 961–973.
40. Ryan, Q.C., Headlee, D., Acharya, M., Sparreboom, A., Trepel, J.B., Ye, J., Figg, W.D., Hwang, K., Chung, E.J., Murgo, A., et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 23 (2005), 3912–3922.
41. Schlee, M., Hölzel, M., Bernard, S., Mailhammer, R., Schuhmacher, M., Reschke, J., Eick, D., Marinkovic, D., Wirth, T., Rosenwald, A., et al. C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma. Int. J. Cancer 120 (2007), 1387–1395.
42. Schlee, M., Schuhmacher, M., Hölzel, M., Laux, G., Bornkamm, G.W., c-MYC impairs immunogenicity of human B cells. Adv. Cancer Res. 97 (2007), 167–188.
43. Soucek, L., Whitfield, J.R., Sodir, N.M., Massó-Vallés, D., Serrano, E., Karnezis, A.N., Swigart, L.B., Evan, G.I., Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 27 (2013), 504–513.
44. Stengel, S., Fiebig, U., Kurth, R., Denner, J., Regulation of human endogenous retrovirus-K expression in melanomas by CpG methylation. Genes Chromosomes Cancer 49 (2010), 401–411.
45. Strissel, P.L., Ruebner, M., Thiel, F., Wachter, D., Ekici, A.B., Wolf, F., Thieme, F., Ruprecht, K., Beckmann, M.W., Strick, R., Reactivation of codogenic endogenous retroviral (ERV) envelope genes in human endometrial carcinoma and prestages: Emergence of new molecular targets. Oncotarget 3 (2012), 1204–1219.
46. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., Mesirov, J.P., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005), 15545–15550.
47. Talevich, E., Shain, A.H., Botton, T., Bastian, B.C., CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLoS Comput. Biol., 12, 2016, e1004873.
48. Tsai, H.C., Li, H., Van Neste, L., Cai, Y., Robert, C., Rassool, F.V., Shin, J.J., Harbom, K.M., Beaty, R., Pappou, E., et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21 (2012), 430–446.
49. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
50. Weiser, T.S., Guo, Z.S., Ohnmacht, G.A., Parkhurst, M.L., Tong-On, P., Marincola, F.M., Fischette, M.R., Yu, X., Chen, G.A., Hong, J.A., et al. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J. Immunother. 24 (2001), 151–161.
51. Wherry, E.J., Kurachi, M., Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15 (2015), 486–499.
52. Wherry, E.J., Ha, S.J., Kaech, S.M., Haining, W.N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J.N., Barber, D.L., Ahmed, R., Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27 (2007), 670–684.
53. Wrangle, J., Wang, W., Koch, A., Easwaran, H., Mohammad, H.P., Vendetti, F., Vancriekinge, W., Demeyer, T., Du, Z., Parsana, P., et al. Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget 4 (2013), 2067–2079.
54. Zahnow, C.A., Topper, M., Stone, M., Murray-Stewart, T., Li, H., Baylin, S.B., Casero, R.A. Jr., Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy. Adv. Cancer Res. 130 (2016), 55–111.
55. Zehn, D., Wherry, E.J., Immune Memory and Exhaustion: Clinically Relevant Lessons from the LCMV Model. Adv. Exp. Med. Biol. 850 (2015), 137–152.